Rune Labs

San Francisco, CaliforniaFounded 201811–50 employeesrunelabs.io

Neuromodulation
Wearables
Parkinson's disease

Rune Labs is a San Francisco-based software and data platform focused on neuromodulation and brain health. The company develops tools that make clinical brain data useful for clinicians, researchers, therapy developers, and patients with neurological disorders, including Parkinson’s disease.

Visit runelabs.io ↗

Patents: 10
Founded: 2018
Employees: 11–50

reccy insights

Written by reccy's AI from company sites, press and funding records · updated Oct 2026

Recent highlights

Rune Labs expanded its clinical and commercial focus across 2025 and early 2026. On Mar 5, 2025, it launched an AI-enabled Parkinson’s disease care-management service combining real-time monitoring with personalized coaching. On May 29, 2025, Rune Labs and the Parkinson’s Foundation launched a clinical program connecting genetic biomarkers from PD GENEration with digital biomarkers collected through StrivePD, creating a pathway for more precise Parkinson’s research and care. The company also raised $11.2 million in a venture round announced on Jun 30, 2025, bringing cumulative funding to approximately $52.5 million across five rounds. On Oct 21, 2025, Adam Pellegrini joined the board as an independent director, adding experience in digital health, reimbursement, and payer strategy. On Jan 8, 2026, former Tempus executive Amy Franzen became CEO, while founder Brian Pepin moved into the President, Biopharma and Platform role. The leadership transition suggests a deliberate effort to scale partnerships, research programs, and AI-enabled neurology care while retaining founder involvement in platform and biopharma activities.

Market position

Rune Labs operates at the intersection of digital health, neuromodulation software, clinical research infrastructure, and wearable-based neurological monitoring. Its differentiation is the combination of StrivePD’s patient and clinician workflow, Apple Watch-derived symptom data, clinical-trial capabilities, and infrastructure for heterogeneous neurophysiological data. This gives Rune Labs a broader operating model than a standalone symptom-tracking application: the same ecosystem can support care delivery, longitudinal data collection, trial recruitment, and therapy development. The company’s focus overlaps with digital therapeutics, remote patient monitoring, clinical-trial technology, and neuromodulation-platform providers, but the available company record does not identify a reliable named competitor set for direct comparison. Its strongest demonstrated beachhead is Parkinson’s disease, supported by the StrivePD ecosystem and the 2025 Parkinson’s Foundation program correlating genetic and digital biomarkers.

Growth & opportunities

Rune Labs has followed a staged trajectory from platform formation to disease-specific care delivery and clinical research. Founded in 2018, it raised $1.46 million in 2019 and $5 million in 2020 before closing a $22.8 million Series A led by Eclipse Ventures on Sep 16, 2021. A $12 million venture round followed on Jan 11, 2024, and the company added another $11.2 million on Jun 30, 2025. The five-round history and approximately $52.5 million in cumulative funding indicate sustained financing through the transition from infrastructure development to applied neurology products. Product expansion accelerated in 2025: Rune Labs launched AI-supported personalized coaching for Parkinson’s care in March and began a genetics-plus-digital-biomarker clinical program with the Parkinson’s Foundation in May. The January 2026 appointment of Amy Franzen as CEO, alongside Brian Pepin’s shift to President, Biopharma and Platform, marks another inflection point toward partnerships, research, and broader AI-enabled neurology care.

Written by reccy's AI from company sites, press and funding records · updated Oct 2026

What makes Rune Labs distinct

reccy insights

What makes Rune Labs distinct

01Combines clinical brain data, software, and neuromodulation expertise to support precision neurology.
02Its StrivePD ecosystem received FDA clearance for Parkinson’s disease monitoring through Apple Watch.
03StriveStudy is designed to accelerate clinical trials for precision neurology therapies.
04Emphasizes patient privacy, dignity, data security, and ethical product development.
05Works across patients, clinicians, researchers, and industry partners rather than serving only one stakeholder group.

Technology & products3

Technology & products

StrivePD
A care delivery ecosystem for Parkinson’s disease that collects symptom data via Apple Watch and a patient app, providing clinicians with dashboards and workflows to support personalized care and clinical-trial connections.
Rune Labs Clinical Trial Platform
A platform supporting clinical trials through data collection, enriched recruitment, and synthetic control cohorts built from real-world data from patients with neurodegenerative disease.
Rune Labs Data Infrastructure Platform
A software-as-a-service platform that securely integrates and manages heterogeneous neurophysiological and wearable data for search, filtering, collaboration, and neuromodulation therapy development.

Patents10

USPTO, assigned to Rune Labs

Show all 10 patents

Recent updates5

Launches, partnerships and team changes from press coverage

Jan 8, 2026Team change
Rune Labs appointed former Tempus executive Amy Gordon Franzen as CEO, while co-founder Brian Pepin became President, Biopharma and Platform, focusing on partnerships and research.
morningstar.com
Oct 21, 2025Team change
Rune Labs appointed Adam Pellegrini as an independent board member, adding experience in AI-driven digital health, reimbursement, and payer strategy to support the StrivePD ecosystem.
morningstar.com
May 29, 2025Product launch
Rune Labs and the Parkinson’s Foundation launched a clinical program to correlate genetic and digital biomarkers for Parkinson’s disease, leveraging StrivePD and the Parkinson’s Foundation’s PD GENEration initiative.
businesswire.com
May 29, 2025Partnership
Rune Labs and the Parkinson’s Foundation announced a partnership to launch a clinical program correlating genetic and digital biomarkers for Parkinson’s disease through AI-driven software and genetic testing initiatives.
businesswire.com
Mar 5, 2025Product launch
Rune Labs launched a personalized Parkinson’s disease care service combining AI-driven insights, real-time health monitoring, and expert coaching.
businesswire.com

Show all 5 updates

In the Cortex

Rune Labs Launches Parkinson’s AI Companionbusinesswire.com · Apr 13, 2026

Similar companies

Show all 6 companies

About Rune Labs

Products: StrivePD, Rune Labs Clinical Trial Platform, Rune Labs Data Infrastructure Platform
Leadership: Amy Franzen, CEOBrian Pepin, President, Biopharma and PlatformLuke Gilson, Engineering Manager
Focus areas: Digital health, neuromodulation, neurology, parkinson's disease, clinical research, healthcare software, brain data, wearables
Headquarters: San Francisco, California
Founded: 2018
Employees: 11–50
Patents granted: 9 (Crunchbase)
Trademarks: 4